CELLTRION
23.9.2021 09:02:05 CEST | Business Wire | Press release
Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
Celltrion USA will make deliveries to approximately 25,000 U.S. CONUS locations to support military bases, long-term care facilities, community testing sites, critical infrastructure, and other designated places on a weekly basis.
The DLA estimates its order volume to be as much as $626 million considering the change in demand by the COVID-19 community transmission rate in the U.S.
Celltrion believes that this procurement contract underscores Celltrion's quality, production and supply capabilities as the deal has been awarded after the Department of Defense’s rigorous verification. Celltrion has already proven the quality and safety of DiaTrustTM earlier this year as the product obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on April 16. Celltrion’s supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea. In addition, Celltrion USA emphasized the firm’s drug distribution performance in the US market for the last three years to demonstrate its ability to perform timely deliveries to 25,000 designated places in the U.S., at a competitive price.
Unlike other COVID-19 Antigen Rapid Test kits, DiaTrustTM is a product that applied two antibodies binding COVID-19 virus to both N-protein and S-protein, respectively, resulting in improved sensitivity of 93.3% and specificity of 99.0%. Also, the infection can be diagnosed within only 15 minutes.
The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability. With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio,” said Bonjoong Kim, CEO of Celltrion USA.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC’s approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005328/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 11:58:00 CET | Press release
Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U
Komainu Completes Two-Way Digital Asset Transfers for First Abu Dhabi Bank as Institutional Custody Framework Goes Live3.11.2026 10:30:00 CET | Press release
Komainu, a regulated digital asset services provider and custodian backed by Laser Digital and Blockstream, has completed the two-way transfer of a portfolio of digital assets with First Abu Dhabi Bank (FAB) through the institutional digital asset custody framework the two firms have established. The transfers settled instantly. The milestone marks the operationalisation of Komainu’s collaboration with FAB Global Markets, integrating regulated digital asset custody and connectivity capabilities with FAB’s existing infrastructure. The transfers demonstrate the bank’s ability to move digital assets both into and out of the custody environment, validating the infrastructure required to support institutional digital asset activity. The framework has also been designed to support future institutional financing solutions, including lending backed by digital assets held in regulated custody. This provides a foundation for FAB to further integrate digital assets into its financial markets infr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom